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Edited by Veli-Pekka LehtoAbstract The ability of inﬂammatory cytokine TGF-b1 to alter
endothelial cell phenotype suggests its role in the regulation of
vascular endothelial cell permeability. We demonstrate that
depletion of TGF-b1 receptor ALK5 and regulatory protein
Smad4, but not ALK1 receptor attenuates TGF-b1-induced per-
meability increase and signiﬁcantly inhibits TGF-b1-induced EC
contraction manifested by actin stress ﬁber formation and in-
creased MLC and MYPT1 phosphorylation. Consistent with
these results, EC treatment with SB 431542, an inhibitor of
ALK5 but not ALK1 receptor, signiﬁcantly attenuates TGF-
b1-induced permeability. Thus, our data demonstrate for the ﬁrst
time direct link between TGF-b1-mediated activation of ALK5/
Smad and EC barrier dysfunction.
 2005 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Transforming growth factor beta 1 (TGF-b1) belongs to a
family of inﬂammatory cytokines involved in the regulation
of cellular diﬀerentiation, proliferation, migration, and pro-
tein expression. Cellular responses to TGF-b1 are elicited
via speciﬁc transmembrane type I and type II Ser/Thr kinase
receptors [1,2]. The signaling pathway is initiated by TGF-b1
binding to TGF-b type II receptor (TbRII receptor). After li-
gand binding, TbRII recruits and phosphorylates TGF-b type
I receptor (TbRI) also known as activin receptor-like kinase 5
(ALK5) [2], which transduces intracellular signals via activa-
tion of Smad2/3 proteins [2]. In addition to ALK5, endothe-
lial cells (EC) express a second TbRI variant, ALK1, which
can phosphorylate Smad1 and Smad5 [2,3]. Both TbRI vari-Abbreviations: ALK, activin receptor-like kinase; EC, endothelial cell;
MLC, myosin light chain; MYPT1, myosin phosphatase regulatory
subunit 1; RDU, relative density units; TER, transendothelial electri-
cal resistance; TGFb1, transforming growth factor beta 1; TbRI, TGF-
b type I receptor; TbRII, TGF-b type II receptor
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lium [4]. Nine distinct vertebrate Smads can be classiﬁed into
three groups, which include receptor-activated Smads 1/2/3/5/
8 (rSmads), common Smads (Smad4 and x-Smad4b), and
inhibitory Smads 6/7 [5]. rSmads become activated by recep-
tor-mediated phosphorylation. Phosphorylated rSmads form
heteromeric complexes with the common partner Smad4.
These complexes translocate to the nucleus, where they regu-
late transcription of target genes. Thus, Smad2 and Smad3
act synergistically in tandem with Smad4, while Smad7 antag-
onizes TGF-b1 signaling by preventing Smad2/3 access to
and phosphorylation by activated TbRI [5]. Stimulation of
EC by TGF-b1 causes phosphorylation of Smad1/2/5 [4,6].
Thus, in contrast to other cell types, TGF-b1 in endothelium
may activate two receptors (ALK1 and ALK5) coupled to
Smad cascades [2].
In vitro studies demonstrate that overexpression of constitu-
tively active ALK1 and ALK5 mutants leads to phosphoryla-
tion of Smads and F-actin rearrangement in epithelial cells [7],
suggesting direct role for ALK/Smad signaling in cytoskeletal
remodeling. We and others have previously reported that
TGF-b1 induces barrier dysfunction in pulmonary EC and de-
scribed signaling mechanisms involved in TGF-b1-induced
permeability and barrier failure [8–11]. The results of this
study show that speciﬁc depletion or pharmacological inhibi-
tion of ALK5 and Smad4 proteins signiﬁcantly attenuated
TGF-b1-induced decrease in transendothelial electrical resis-
tance (TER), stress ﬁber formation, and phosphorylation of
myosin light chains and myosin-speciﬁc phosphatase indicat-
ing the involvement of ALK/Smad signaling in TGF-b1-
induced pulmonary EC cytoskeletal remodeling and barrier
compromise.2. Materials and methods
2.1. Reagents
Site-speciﬁc phospho-myosin phosphatase regulatory subunit 1
(MYPT1) antibody was obtained from Upstate Biotechnology (Lake
Placid, NY), ALK5 and ALK1 antibodies were from Abgent (San Die-
go, CA), Smad4 antibody was from BD Biosciences (San Jose, CA), di-
phospho-myosin light chain (MLC) and phospho-Smad2 antibodies
were from Cell Signaling (Beverly, MA), b-tubulin antibody was from
Covance Inc. (Berkeley, CA). Texas Red phalloidin and Alexa Flour
488 conjugated secondary antibodies were purchased form Molecular
Probes (Eugene, OR). Human TGF-b1 was obtained from R&Dation of European Biochemical Societies.
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Tocris (Ellisville, MO). Unless speciﬁed, biochemical reagents were ob-
tained from Sigma (St. Louis, MO).
2.2. Cell cultures
Bovine pulmonary artery endothelial cells were obtained from
American Type Tissue Culture Collection, (Rockville, MD; culture
line-CCL 209) and cultured as described previously [12].
2.3. Depletion of endogenous ALK1, ALK5 and Smad4 in EC
To reduce the content of endogenous ALK1, ALK5 and Smad4 pro-
teins EC were treated with ALK1, ALK5 or Smad4-speciﬁc small
interfering RNA (siRNA) duplex oligonucletides, which guide se-
quence-speciﬁc degradation of the homologous mRNA [13]. siRNAs
were selected using Qiagen Silence RNA Design Tool and purchased
from Qiagen (Valencia, CA) in annealed double stranded form of
HPP grade purity. To design ALK1-speciﬁc siRNA oligomer, Homo
sapiens ALK1 mRNA sequence (GenBank Accession No.
NM_000020) was subjected to NCBI Blast search against Bos taurus
EST DNA library, and DNA target sequence: AGTTCGTCAAC-
CACTACTGCT was selected from 487-bp cDNA sequence (Accession
No. AW447816), which is highly homologous to the fragment ofHomo
sapiens ALK1 mRNA ﬂanked by nucleotides 247–713. The following
21 base pair duplexes of siRNA were used for ALK1: sense 5 0-UUC-
GUCAACCACUACUGCUUU-3 0 and antisense 5 0-AGCAGUAG
UGGUUGACGAACU. Target sequence for the ALK5: AACA-
TATTGCTGCAACCAGGA was selected from Bos taurus ALK5
mRNA sequence (Accession No. NM_174621). The following siRNA
duplexes were used for ALK5: sense 5 0-CAUAUUGCUGCAAC-
CAGGAtt-30 and antisense 5 0-UCCUGGUUGCAGCAAUAUGtt-
3 0. For the selection of the Smad4 siRNA Homo sapiens Smad4
(MADH4) mRNA sequence (GenBank Accession No. NM_005359)
was subjected to NCBI Blast search against Bos taurus EST cDNA li-
brary, and DNA target sequence: AAGGTCTTTGATTTGCGTCAG
was selected from 515-bp cDNA sequence (Accession No. BM364130),
which is highly homologous to a part of Homo sapiens Smad4 mRNA
ﬂanked by nucleotides 1323–1828. The following 21 base pair duplexes
of siRNA were used for Smad4: sense 5 0-GGUCUUUGAUUUGC-
GUCAGtt-3 0 and antisense 5 0-CUGACGCAAAUCAAAGACCtt-30.
Non-speciﬁc, non-silencing FILuciferase GL2 duplex ﬂuorescently la-
beled on the sense strand with 5 0-Fluorescein (Dharmacon Research,
Lafayette, CO) was used as a control treatment. EC were grown to
70% conﬂuence, and the transfection of siRNA (ﬁnal concentration
100 nM) was performed using DharmaFECT1 transfection reagent
according to the manufacturers protocol. Forty-eight hours post-
transfection cells were harvested and used for experiments.2.4. Semi-quantitative RT-PCR analysis
To estimate the amount of ALK1, ALK5, and Smad4 RNAs in lung
EC after siRNA treatment, total RNA (0.5 lg) isolated from control
and treated cells was subjected to PCR in 25-ll reaction mixture using
reagents from Superscript One Step RT-PCR kit (Invitrogen, Carls-
bad, CA). 18S ribosomal RNA 184 bp fragment, used as an internal
control for normalization, was ampliﬁed using 40 nM primers from
TaqMan Gold RT-PCR Core Reagents Kit (Applied Biosystems, Fos-
ter City, CA). To amplify 260 bp fragment of ALK1 cDNA, 200 nM
each of the following primers were used: forward, 5 0-CAGGGTAG
CGATTACCTGGACATT-3 0; reverse, 5 0-CACACCACCTTCTT
CATGTCCTCA-3 0. The ampliﬁed cDNA corresponds to nucleotides
21–280 in Bos Taurus cDNA sequence (Accession No. BI976577)
highly homologous to part of Homo sapiens ALK1 mRNA (nucleo-
tides 1322–1749). For the ampliﬁcation of 259 bp fragment of ALK5
cDNA, 200 nM each of the following primers were used: forward,
5 0-CCACGAGACAGGCCATTTGTATGT-3 0; reverse, 5 0-AGGG
ATCCTCTTCATTTGGCACTC-30. The ampliﬁed cDNA corre-
sponds to nucleotides 268–526 in Bos Taurus ALK5 sequence. To am-
plify 224 bp part of SMAD4 cDNA, 200 nM each of the following
primers were used: forward, 5 0-CACAGGACAGAAGCCATTGA-
GAGA-30; reverse, 5 0-CGGTGACACTGACGCAAATCAAAG-3 0.
The ampliﬁed cDNA corresponds to nucleotides 24–247 in Bos Taurus
cDNA sequence (Accession No. BM364130) highly homologous to
part of Homo sapiens SMAD4 mRNA. The PCR products were ana-
lyzed by agarose gel electrophoresis.2.5. Immunoﬂuorescent staining and endothelial cell imaging
Endothelial cells grown on glass coverslips were transfected with
speciﬁc siRNA duplex oligonucletides followed by TGF-b1 treatment,
then subjected to double immunoﬂuorescent staining for di-phospho-
MLC and F-actin as described previously [12,14,15].
2.6. Western immunoblotting
Protein extracts were separated by SDS–PAGE, transferred to nitro-
cellulose membrane and probed with speciﬁc antibodies as previously
described [15,16]. Immunoreactive proteins were detected using en-
hanced chemiluminescent detection system (ECL) according to the
manufacturers protocol (Amersham, Little Chalfont, UK).
2.7. Measurement of transendothelial electrical resistance
Decreases in monolayer resistance to electrical current ﬂow, which
correlated with paracellular gap formation were measured according
to the method described by Tiruppathi and co-workers [17]. The total
electrical resistance was measured dynamically across the monolayer
using an electrical cell-substrate impedance sensing system (Applied
Biophysics, Troy, NY) and was determined by the combined resistance
between the basal surface of the cell and the electrode, reﬂective of fo-
cal adhesion, and the resistance between the cells, as described previ-
ously [14,16].
2.8. Statistical analysis
Results are expressed as means ± S.D. of three to ﬁve independent
experiments. Stimulated samples were compared with controls by un-
paired Students t test. For multiple-group comparisons, one-way anal-
ysis of variance (ANOVA) followed by the post hoc Fishers test were
used. P < 0.05 was considered statistically signiﬁcant.3. Results
3.1. Eﬀect of ALK1, ALK5 and Smad4 depletion on TGF-b1-
induced lung endothelial permeability
We and others have previously shown that TGF-b1 decreases
lung EC TER, reﬂecting increased permeability [8,10,11,18]. To
directly assess a role of ALK receptors in TGF-b1-induced drop
in TER, we decreased a content of endogenous ALK1 and
ALK5 using siRNA approach. In these series of experiments,
EC were incubated with ALK1- and ALK5-speciﬁc siRNA or
treated with non-speciﬁc RNA duplex oligonucelotide for
48 h. Results of semi-quantitative RT-PCR and protein expres-
sion detected byWestern blot with speciﬁc antibodies shown on
the right panels in Fig. 1 conﬁrmALK1 and ALK5RNA deple-
tion caused by ALK1 and ALK5-speciﬁc siRNA duplexes, as
compared toEC treatedwithnon-speciﬁcRNA.After treatment
with speciﬁc siRNA, EC were stimulated with TGF-b1 (10 ng/
ml), and measurements of TER were performed as described
in Section 2. Depletion of ALK5 completely abolished TGF-
b1-induced permeability increase (Fig. 1A), whereas depletion
of ALK1 was without eﬀect (Fig. 1B). These data suggest direct
involvement of ALK5 receptor in the TGF-b1-induced perme-
ability. These results were conﬁrmed by complimentary experi-
ments with SB431542, a speciﬁc pharmacological inhibitor of
ALK4, ALK5, ALK7 receptors, but not of ALK1 receptor
(Fig. 1C) [19]. EC monolayers were treated with SB431542
(10 lM, 1 hr) followed by TGF-b1 stimulation (10 ng/ml). Pre-
treatment with SB431542 itself initially decreased TER, but
more importantly, completely abolished TER decline in re-
sponse to TGF-b1 (Fig. 1C-1). Interestingly, post-treatment of
EC with SB431542 after 2 or 4 h of TGF-b1 stimulation also
led to restoration of battier properties, indicating involvement
of sustained TGF-b1-induced activation of ALK5 receptor in
ECbarrier dysfunction (Fig. 1C-2).Next,we examined the involve-
ment of Smad4 in TGF-b1-induced EC barrier compromise.
Fig. 1. Eﬀect of ALK1, ALK5 and Smad4 depletion on TGF-b1-induced EC permeability. Panels A, B and D – Endothelial cells were plated on gold
microelectrodes and incubated with siRNA to ALK5 (Panel A), ALK1 (Panel B) or Smad4 (Panel D), or treated with non-speciﬁc RNA duplex
oligonucelotide as described in Section 2 and used for TER measurements. Cells were stimulated with TGF-b1 (10 ng/ml) at the time indicated by
arrow. Shown are results of ﬁve independent experiments. Right panels conﬁrm RNA depletion and decrease in protein production induced by
ALK1, ALK5, and Smad4-speciﬁc siRNA duplexes, as compared to treatment with non-speciﬁc RNA duplexes, which were veriﬁed by semi-
quantitative RT-PCR and immunoblotting analysis. Panel C1 – Cells were pretreated with SB 431542 inhibitor (10 lM for 1 h, indicated by ﬁrst
arrow) followed by TGF-b1 stimulation (10 ng/ml, indicated by second arrow), and TER was monitored for 13.5 h. Panel C2 – Cells were stimulated
with TGF-b1 (10 ng/ml, indicated by ﬁrst arrow) and after 2 or 4 h were treated with SB431542 inhibitor (10 lM for 1 h, indicated by second and
third arrow, respectively), and TER was monitored for 13.5 h. Results are representative of three independent experiments.
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similar to procedures for ALK1 and ALK5 depletion described
above, and TER changes after TGF-b1 (10 ng/ml) treatment
were monitored (Fig. 1D, right panels). Semi-quantitative RT-
PCR and results of immunoblotting analysis with speciﬁc anti-
body (Fig. 1D, insets) conﬁrm RNA and protein depletion
caused by Smad4 siRNA duplexes, as compared to non-speciﬁc
RNA duplexes. Depletion of Smad4 signiﬁcantly protected EC
monolayers against TGF-b1-induced increased permeability
(Fig. 1D). These results suggest an important role for AKL5/
Smad4 signaling in EC barrier dysfunction in response to
TGF-b1.
3.2. Eﬀect of ALK1, ALK5 and Smad4 depletion on TGF-b1-
induced cytoskeletal remodeling
To further investigate the role of ALK/Smad signaling in the
TGF-induced barrier dysfunction, we examined eﬀects of
ALK/Smad depletion on TGF-b1-induced cytoskeletal remod-
eling. After ALK1, ALK5 or Smad4 depletion with appropri-
ate siRNA, EC were exposed to TGF-b1 (10 ng/ml, 3 h), and
F-actin remodeling and diphospho-MLC accumulation was
examined by double imminoﬂuorescent staining as described
in Section 2. Fig. 2A demonstrates eﬀects of TGF-b1 on the
EC monolayer integrity. Figs. 2B and C represent high magni-
ﬁcation images of single cells depicting details of cytoskeletal
remodeling and intracellular localization of phosphorylated
MLC. EC pretreatment with ALK1-, ALK5- or Smad4-spe-
ciﬁc siRNAs or cell pretreatment with non-speciﬁc RNA did
not aﬀect basal F-actin arrangement in non-stimulated EC
characterized by actin ﬁbers assembled in cortical rim (Fig.
2A and B, upper panels) and showed low levels of phosphory-
lated MLC (Fig. 2B, middle panels), which co-localized with
actin ﬁlaments (Fig. 2B, lower panels). TGF-b1 stimulation
of EC treated with ALK1-speciﬁc siRNA or with non-speciﬁc
RNA induced robust stress ﬁber and paracellular gap forma-
tion (Fig. 2A, lower panels) accompanied by dramatic increase
in the amount of phosphorylated MLC, which colocalized with
stress ﬁbers (Fig. 2C, two left columns). In contrast, pretreat-
ment with ALK5- or Smad4-speciﬁc siRNA signiﬁcantly atten-
uated TGF-b1-induced stress ﬁbers, paracellular gapFig. 2. Eﬀect of ALK1, ALK5, and Smad4 depletion on TGF-b1-induced cyt
siRNA to ALK1, ALK5 or Smad4, or treated with non-speciﬁc RNA duplex
(10 ng/ml, 3 h). Panel A – EC monolayers were stained for F-Actin with Texa
C – EC were subjected to double immunoﬂuorescent staining with Texas Red
pp-MLC antibody (Panels B and C, middle images). Lower images in Panels
representative of three independent experiments.formation and MLC phosphorylation (Fig. 2A and C, two
right columns). These results are highly consistent with diﬀer-
ential eﬀects of ALK1, ALK5, and Smad4 depletion on TGF-
b1-induced TER decline in lung EC and strongly suggest the
importance of ALK5 and Smad4 in TGF-mediated endothelial
cytoskeletal remodeling.
3.3. Eﬀect of ALK1, ALK5, and Smad4 depletion on TGF-b1-
activated intracellular signaling
In the next experiments, we explored the eﬀects of ALK/
Smad depletion on TGF-b1-mediated activation of signal
pathways associated with cytoskeletal remodeling. We have
previously reported that EC treatment with TGF-b1 induced
activation of regulatory Smad2 [10] known to mediate signal-
ing from ALK5 receptor to downstream targets [2], and in-
creased phosphorylation of MLC and MYPT1, which are
involved in remodeling of cell cytoskeleton and cell contrac-
tion [20,21]. In these experiments, EC were treated with
ALK1-, ALK5-, Smad4-speciﬁc siRNA, or non-speciﬁc
RNA, or cells were left untreated, and phosphorylation of
Smad2, MLC, and MYPT1 in response to stimulation with
TGF-b1 (10 ng/ml, 3 or 6 h) was assessed by immunoblotting
with speciﬁc antibodies (Fig. 3) as described in Section 2.
Equal protein loading was conﬁrmed by re-probing of mem-
branes with antibody against housekeeping protein b-tubulin.
Consistent with the results of previous experiments (Figs. 1
and 2), depletion of ALK5 and Smad4 dramatically attenuated
TGF-b1-induced phosphorylation of Smad2, MLC, and
MYPT1, whereas depletion of ALK1 had no eﬀect on TGF-
b1-induced protein phosphorylation.
4. Discussion
Disturbances in EC barrier regulation are hallmark of lung
inﬂammation, angiogenesis, and cancer.Growing evidence indi-
cates that inﬂammatory cytokines such as TGF-b1 increase lung
EC permeability in vitro and in vivo [8,10,11,18]. In ECs, TGF-
b1 induces activation ofALK1andALK5 receptors and triggers
signaling pathways involved in angiogenesis, cell proliferation
and migration [6,22,23]. Although crosstalk between ALK1oskeletal remodeling. EC grown on glass coverslips were incubated with
oligonucelotide as described in Section 2 followed byTGF-b1 treatment
s Red phalloidin. Paracellular gaps are shown by arrows. Panels B and
phalloidin to visualize F-actin (panels B and C, upper images) and anti-
B and C represent overlay of F-actin and pp-MLC staining. Results are
Fig. 2 (continued)
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gested [24,25], precise role for ALK1 andALK5 in regulation of
TGF-b1-induced lung EC permeability remains unknown.
TGF-b1-induced permeability in EC of diﬀerent origin may be
regulated by Rho-dependent pathways, MAP kinases, MLC ki-
nase, PKA, and by microtubule dynamics [8–10,18]. However,
upstream mechanisms of TGF-induced actin remodeling and
EC barrier dysfunction remain largely unexplored.
Complementary molecular and pharmacological approaches
used in this study demonstrate for the ﬁrst time speciﬁc involve-
ment of ALK5 in TGF-induced EC permeability increase and
actin cytoskeletal remodeling. Our results strongly suggest that
ALK5/Smad4 activation triggers TGF-b1-induced stress ﬁber
formation and phosphorylation of MLC, MYPT1 and Smad2.
Immunoﬂuorescent analysis and biochemical assays showedinhibitory eﬀects of ALK5 depletion on TGF-induced stress ﬁ-
ber formation and phosphorylation of MLC, MYPT1, and
Smad2, associated with EC barrier dysfunction. Furthermore,
depletion of Smad4 also abolished TGF-b1-induced stress ﬁber
formation, MLC phosphorylation and signiﬁcantly attenuated
EC barrier dysfunction suggesting that Smad4 is downstream
eﬀector ofALK5 involved inALK/Smad pathway of EC barrier
dysfunction. One of the known functions of Smad4 is transport
ofALK-activated rSmads to thenucleus and regulation of target
gene transcription, whichmay suggest an additional mechanism
ofTGF-mediatedECbarrier regulation via activation of speciﬁc
gene transcription. Our data also show that depletion of Smad4
signiﬁcantly attenuated but not completely abolished TGF-b1-
induced Smad2 phosphorylation (Fig. 3). We can speculate that
formation of Smad2/4 complexes may induce additional
Fig. 3. Eﬀect of ALK1, ALK5 and Smad4 depletion on TGF-b1-induced cellular signaling. EC grown in D35 dishes were incubated with siRNA to
ALK1, ALK5 or Smad4, or treated with non-speciﬁc RNA duplex oligonucelotide as described in Section 2 followed by TGF-b1 treatment (10 ng/
ml, 3 h). Phosphorylation of speciﬁc proteins was detected by western blot with p-Smad2, pp-MLC, or p-MYPT1 (Thr850) antibodies. The lower
panels depict results of quantitative analysis of protein phosphorylation expressed in relative density units (RDU) and performed by scanning
densitometry of the membranes. Equal protein loading were conﬁrmed by re-probing of membranes with b-tubulin antibody. Shown are
representative results from three independent experiments.
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mation by reduction of Smad4 content may lead to decrease in
Smad2 phosphorylation. In further studies, we plan to investi-
gate ALK5–Smad2/3–Smad4 interaction in more detail and
clarify this question.
As molecular basis of acute lung injury is poorly understood,
these studies provide a highly novel and critical information
about signaling pathways and cytoskeletal mechanisms of
TGF-b1-induced acute EC barrier dysfunction.
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